CN105853492B - 一种治疗带状疱疹的膏药及其制作方法 - Google Patents
一种治疗带状疱疹的膏药及其制作方法 Download PDFInfo
- Publication number
- CN105853492B CN105853492B CN201610328743.0A CN201610328743A CN105853492B CN 105853492 B CN105853492 B CN 105853492B CN 201610328743 A CN201610328743 A CN 201610328743A CN 105853492 B CN105853492 B CN 105853492B
- Authority
- CN
- China
- Prior art keywords
- weight
- dosage
- plaster
- main
- materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011505 plaster Substances 0.000 title claims abstract description 33
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title description 6
- 239000000463 material Substances 0.000 claims abstract description 37
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 19
- 241000083902 Rhodiola sachalinensis Species 0.000 claims abstract description 18
- 235000012343 cottonseed oil Nutrition 0.000 claims abstract description 18
- 239000002385 cottonseed oil Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 17
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241001145025 Saussurea involucrata Species 0.000 claims abstract description 13
- 229940116229 borneol Drugs 0.000 claims abstract description 13
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 13
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010304 firing Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 239000005556 hormone Substances 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 208000002193 Pain Diseases 0.000 description 7
- 241000133134 Saussurea Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 235000019713 millet Nutrition 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 241001373816 Saussurea laniceps Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004889 cervical nerve Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- -1 glycoside compounds Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种治疗带状疱疹的膏药,其由下述主料和辅料制成,所述主料由下述重量百分比的原料药组成:库页红景天96-98%,绵头雪莲花2-4%;所述辅料由棉花籽油、黄丹和冰片组成,棉花籽油用量为主料重量的2-2.4倍,黄丹用量为主料重量的0.4-0.6倍,冰片用量为主料重量的0.2-0.4倍。该方中所选原料药库页红景天和绵头雪莲花纯天然野生无污染,膏药中不含任何激素不伤害身体,且无毒副作用,经临床试验证实治愈率100%,疗效显著,且疗程短。
Description
技术领域
本发明属于中药技术领域,具体涉及一种治疗带状疱疹的膏药及其制作方法。
背景技术
带状疱疹,民间把这种病称作“蛇神疮”,文献上叫“缠腰火丹”,由水痘-带状疱疹病毒所致的一种沿神经分布的群集疱疹和以神经痛为主要特征的病毒性皮肤病,四季均可发病,多发于春秋季。常见成年人,系统性红斑狼疱、恶性肿瘤,以及较长期接受皮质激素、化疗和放疗的病人,因机体免疫力下降,较正常人明显易感,且病程迁延。
发疹前可有轻度乏力、低热、纳差等全身症状,患处皮肤自觉灼热感或者神经痛,触之有明显的痛觉敏感,持续1~3天,亦可无前驱症状即发疹。好发部位依次为肋间神经、颈神经、三叉神经和腰骶神经支配区域。患处常首先出现潮红斑,很快出现粟粒至黄豆大小的丘疹,簇状分布而不融合,继之迅速变为水疱,疱壁紧张发亮,疱液澄清,外周绕以红晕,各簇水疱群间皮肤正常;皮损沿某一周围神经呈带状排列,多发生在身体的一侧,一般不超过正中线。神经痛为本病特征之一,可在发病前或伴随皮损出现,老年患者常较为剧烈。病程一般2~3周,水疱干涸、结痂脱落后留有暂时性淡红斑或色素沉着。临床常通过以下三点来诊断:1)病变皮肤出现簇集成群水疱,沿一侧周围神经呈带状分布;2)有明显的神经痛,伴局部淋巴结肿大;3)中间皮肤正常。
现有治疗带状疱疹多采用阿普洛素、更普洛素等西药,但是存在治疗效果不理想、不彻底,有后遗证,病人时有痒疼等问题,并且住院时间长,花费高。
发明内容
本发明目的在于克服现有技术缺陷,提供一种疗效显著用于治疗带状疱疹的膏药。
本发明还公开了上述治疗带状疱疹的膏药的制作方法。
为实现上述目的,本发明采用如下技术方案:
一种治疗带状疱疹的膏药,其由下述主料和辅料制成,所述主料由下述重量百分比的原料药组成:库页红景天96-98%,绵头雪莲花2-4%;所述辅料由棉花籽油、黄丹和冰片组成,棉花籽油用量为主料重量的2-2.4倍,黄丹用量为主料重量的0.4-0.6倍,冰片用量为主料重量的0.2-0.4倍。
具体的,所述主料优选由下述重量百分比的原料药组成:库页红景天97%,绵头雪莲花3%;棉花籽油用量为主料重量的2倍,黄丹用量为主料重量的0.4倍,冰片用量为主料重量的0.2倍。
具体的,所述主料优选由下述重量百分比的原料药组成:库页红景天97%,绵头雪莲花3%;棉花籽油用量为主料重量的2.2倍,黄丹用量为主料重量的0.5倍,冰片用量为主料重量的0.3倍。
上述治疗带状疱疹的膏药的制作方法,其包括如下步骤:
步骤一:按比例取上述各原料,然后将干燥的库页红景天(根、茎)和绵头雪莲花加工成细粉,混匀后备用;
步骤二:将棉花籽油倒入锅中,文火熬制(2-3小时),待油温升至280℃以上时,关火;
步骤三:当油温降到70±5℃时,搅拌条件下把步骤一产物倒入锅中,再次开火并文火熬制(2-4小时);
步骤四:当温度达到280℃以上时(优选280-320℃;当温度达到280℃以上时药浆变黑),关火,搅拌条件下加入黄丹并搅拌15min以上(此时黑膏滴水成珠,手捏不软不硬);
步骤五:当温度降到70-80℃时,搅拌条件下加入冰片,搅拌均匀(一般搅拌15-20min),即得。本发明膏药当天配料,当天熬制,不需要浸泡原料。
用法用量:外用。使用时,将膏药烤化后贴于患处,每帖贴3天,一帖为一个疗程,一般1-3个疗程即痊愈且无伤疤、无后遗症、无副作用,治愈率达100%。本发明治疗带状疱疹的膏药的最大特点是:无激素、效果好、疗效快、疗效优于目前其它药品;且花钱少,不需住院治疗。男女老少皆可使用,但孕妇禁用。
方中:库页红景天(Rhodiola sachalinensis A. Bor.)是一种珍贵稀有的药用植物,全草均可入药,用药主要是根茎,其性温、涩、坚硬,除了含有主要药效成分红景天苷和甙元酪醇外,还含有丰富的其他苷类化合物、氨基酸、微量元素、挥发油等成分。药理研究证明其具有抗炎、消炎消肿、解毒杀菌、抗病毒、止血镇痛、活血化瘀、收敛等功效。本发明中,优选使用产自青藏的野生库页红景天。本发明经试验发现库页红景天对伤口有愈合作用,其含有细胞激活素,能很快解决病人受损害细胞和死亡细胞问题。绵头雪莲花(学名:Saussurea laniceps),也称作“棉头雪莲”,为菊科风毛菊属的植物,多年生草本植物,是中国的特有植物。生长在海拔4500米以上的岩石、风化流沙处。性温,微苦,无毒,入肝、脾、肾三经。具有抗炎、消炎、补血、止血、镇痛的功效。棉花籽油是棉花籽油精炼后的产物,既可食用也可制成护肤产品,富含高质量的多种维他命、脂肪酸以及甾醇,有消炎的功效。黄丹,又名铅丹、丹粉等;味辛,微寒;外用:拔毒生肌,解毒,收敛,杀虫止痒。冰片,又名片脑、桔片、艾片、龙脑香、梅花冰片等,是由菊科艾纳香茎叶或樟科植物龙脑樟枝叶经水蒸汽蒸馏并重结晶而得;亦有用松节油经一系列化学方法工艺而得;其可用于目赤肿痛,喉痹口疮、疮疡肿痛,溃后不敛等。以上诸药配方科学,配伍合理,相辅相成,用于治疗带状疱疹效果显著。
和现有技术相比,本发明的有益效果:
1)该方中所选原料药库页红景天和绵头雪莲花纯天然野生无污染,膏药中不含任何激素不伤害身体,且无毒副作用,易被病人接受。2)疗效显著,疗程短,具有显著的经济效益和社会效益。
具体实施方式
以下结合实施例对本发明的技术方案作进一步地详细介绍,但本发明的保护范围并不局限于此。
实施例1
一种治疗带状疱疹的膏药,其由下述重量份原料制成:库页红景天97份,绵头雪莲花3份;棉花籽油200份、黄丹40份,冰片20份。
上述治疗带状疱疹的膏药的制作方法,其包括如下步骤:
步骤一:按比例取上述各原料,然后将干燥的库页红景天和绵头雪莲花加工成细粉,混匀后备用;
步骤二:将棉花籽油倒入锅中,文火熬2-3小时,待油温升至280℃左右时,关火;
步骤三:当油温降到70℃左右时,搅拌条件下把步骤一产物倒入锅中,开火并文火熬制2-3小时;
步骤四:当温度达到300℃左右时,关火,搅拌条件下加入黄丹并搅拌约20min,以滴水成珠为度;
步骤五:当温度降到75℃左右时,搅拌条件下加入冰片,搅拌约20min,即得。
本发明膏药当天配料,当天熬制,不需要浸泡原料。
用法用量:外用。使用时,将膏药烤化后贴于患处,每帖贴3天,一帖为一个疗程,孕妇禁用。
实施例2
一种治疗带状疱疹的膏药,其由下述重量份原料制成:库页红景天97份,绵头雪莲花3份;棉花籽油220份、黄丹50份,冰片30份。
上述治疗带状疱疹的膏药的制作方法参照实施例1。
实施例3
一种治疗带状疱疹的膏药,其由下述重量份原料制成:库页红景天96份,绵头雪莲花4份;棉花籽油220份、黄丹50份,冰片30份。
上述治疗带状疱疹的膏药的制作方法参照实施例1。
本发明膏药的临床使用效果:
经500例带状疱疹患者临床试验,患者中,男283例,女217例。临床统计结果显示:治愈率100%。疗效评定标准如下:
治愈:皮损炎症全退,水疱干涸,无新疹,临床症状全部消失,血查疱疹病毒指标呈现阴性;
有效:临床症状减轻;
无效:临床症状无变化或加重。
以下通过典型病例对本发明膏药的疗效作进一步说明。
典型病例1:刘某,男,70岁,5天前右侧腰部皮肤出现丘疹继而变为水疱,使用本发明实施例2膏药1个疗程后,局部疱疹干燥结痂脱落,2个疗程后皮肤完全平复,疼痛消失,血查疱疹病毒指标呈现阴性,无后遗神经痛。
典型病例2:王某,女,58岁,患肺癌,放、化疗后3 个月后,于2013 年春季患带状疱疹,就诊时,右侧腰周围皮肤可见簇而不融合的粟粒至黄豆大丘疹,疼痛剧烈,查水痘疱疹病毒指标呈现阳性,服用阿昔洛韦、消炎痛口服症状无明显改善。使用本发明实施例1膏药3个疗程后,神经剧痛消失;皮损消退,血查疱疹病毒指标呈现阴性,至今未再复发。
典型病例3:李某,男,60岁。胸肋部有带状疱疹、痛觉异常,常有持续性灼痛,使用本发明实施例1膏药1个疗程后,症状明显减轻,2个疗程后治愈,随访至今未再复发。
以下附部分报告病例以辅助说明本发明膏药的疗效:
以上病例均属病情较为严重的带状疱疹,痊愈短的为3 天,时间长的6天痊愈,痊愈率100%,且所有病例无一出现复发及痒痛等后遗症。
Claims (4)
1.一种治疗带状疱疹的膏药,其特征在于,由下述主料和辅料制成,所述主料由下述重量百分比的原料药组成:库页红景天96-98%,绵头雪莲花2-4%;所述辅料由棉花籽油、黄丹和冰片组成,棉花籽油用量为主料重量的2-2.4倍,黄丹用量为主料重量的0.4-0.6倍,冰片用量为主料重量的0.2-0.4倍。
2.如权利要求1所述治疗带状疱疹的膏药,其特征在于,所述主料由下述重量百分比的原料药组成:库页红景天97%,绵头雪莲花3%;棉花籽油用量为主料重量的2倍,黄丹用量为主料重量的0.4倍,冰片用量为主料重量的0.2倍。
3.如权利要求1所述治疗带状疱疹的膏药,其特征在于,所述主料由下述重量百分比的原料药组成:库页红景天97%,绵头雪莲花3%;棉花籽油用量为主料重量的2.2倍,黄丹用量为主料重量的0.5倍,冰片用量为主料重量的0.3倍。
4.权利要求1至3任一所述治疗带状疱疹的膏药的制作方法,其特征在于,包括如下步骤:
步骤一:按比例取上述各原料,然后将干燥的库页红景天和绵头雪莲花加工成细粉,混匀后备用;
步骤二:将棉花籽油倒入锅中,文火熬制,待油温升至280℃以上时,关火;
步骤三:当油温降到70±5℃时,搅拌条件下把步骤一产物倒入锅中,再次开火并文火熬制;
步骤四:当温度达到280℃以上时,关火,搅拌条件下加入黄丹并搅拌15min以上;
步骤五:当温度降到70-80℃时,搅拌条件下加入冰片,搅拌均匀,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610328743.0A CN105853492B (zh) | 2016-05-18 | 2016-05-18 | 一种治疗带状疱疹的膏药及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610328743.0A CN105853492B (zh) | 2016-05-18 | 2016-05-18 | 一种治疗带状疱疹的膏药及其制作方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105853492A CN105853492A (zh) | 2016-08-17 |
CN105853492B true CN105853492B (zh) | 2021-02-09 |
Family
ID=56635035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610328743.0A Expired - Fee Related CN105853492B (zh) | 2016-05-18 | 2016-05-18 | 一种治疗带状疱疹的膏药及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105853492B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739647A (zh) * | 2005-09-08 | 2006-03-01 | 马建国 | 一种治疗带状疱疹的药膏及其制备方法 |
CN101239077A (zh) * | 2008-03-12 | 2008-08-13 | 谭仲尧 | 一种治疗皮肤病的中药 |
CN101249166A (zh) * | 2008-03-28 | 2008-08-27 | 丁昌荣 | 一种治疗带状疱疹的膏药及其制配方法 |
CN103610728A (zh) * | 2013-12-10 | 2014-03-05 | 刘根元 | 一种用纯中药治疗带状疱疹的膏药及其制备方法 |
CN104056018A (zh) * | 2014-06-25 | 2014-09-24 | 姬光勤 | 通络消炎止痛膏 |
CN104415075A (zh) * | 2013-08-20 | 2015-03-18 | 李霞 | 一种治疗带状疱疹艾叶药贴 |
CN104758537A (zh) * | 2015-03-07 | 2015-07-08 | 宋爽 | 一种治疗带状疱疹后神经痛的中药制剂及制备方法 |
-
2016
- 2016-05-18 CN CN201610328743.0A patent/CN105853492B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1739647A (zh) * | 2005-09-08 | 2006-03-01 | 马建国 | 一种治疗带状疱疹的药膏及其制备方法 |
CN101239077A (zh) * | 2008-03-12 | 2008-08-13 | 谭仲尧 | 一种治疗皮肤病的中药 |
CN101249166A (zh) * | 2008-03-28 | 2008-08-27 | 丁昌荣 | 一种治疗带状疱疹的膏药及其制配方法 |
CN104415075A (zh) * | 2013-08-20 | 2015-03-18 | 李霞 | 一种治疗带状疱疹艾叶药贴 |
CN103610728A (zh) * | 2013-12-10 | 2014-03-05 | 刘根元 | 一种用纯中药治疗带状疱疹的膏药及其制备方法 |
CN104056018A (zh) * | 2014-06-25 | 2014-09-24 | 姬光勤 | 通络消炎止痛膏 |
CN104758537A (zh) * | 2015-03-07 | 2015-07-08 | 宋爽 | 一种治疗带状疱疹后神经痛的中药制剂及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105853492A (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106727925B (zh) | 治疗皮肤病的中药膏剂、制备方法及其应用 | |
CN103142903B (zh) | 一种治疗银屑病的中药制剂 | |
KR20160025187A (ko) | 황백 추출물을 이용한 피부냉감용 생약조성물 및 이의 제조방법과 이를 이용한 피부개선제품 | |
CN105853492B (zh) | 一种治疗带状疱疹的膏药及其制作方法 | |
CN102846739B (zh) | 一种治疗肝炎的脐贴膏及其制备方法 | |
CN1634319A (zh) | 一种治疗妇科疾病的中药复方制剂及其制备方法 | |
CN104800799B (zh) | 一种治疗子宫内膜增厚伴卵巢囊肿的中药剂 | |
CN108785559B (zh) | 一种治疗呼吸道感染的药物及其制备方法 | |
CN102451444B (zh) | 一种治疗经痛的中药及其制备方法 | |
CN111265566A (zh) | 一种用于治疗骨折的中药组合物及其制备方法 | |
CN105148147A (zh) | 治疗创伤或褥疮感染的中药及其制备方法 | |
CN100457147C (zh) | 一种治疗妇女更年期综合征的中药组合物及制备方法 | |
CN106266023B (zh) | 一种治疗胃溃疡的药物及其制备方法 | |
CN115120690B (zh) | 一种治疗性早熟的中药组合物及其应用 | |
CN114470121B (zh) | 一种治疗骨关节炎的药物及其制备方法 | |
CN107617009B (zh) | 一种治疗家兔皮肤毛囊炎的复方中草药外用制剂 | |
CN105343816A (zh) | 一种孕妇用口腔溃疡喷剂及其制备方法 | |
CN105560837A (zh) | 治疗皮肤损伤的药物及其制备方法 | |
CN117771166A (zh) | 一种治疗靶向药物相关性皮疹的中药膏剂及其制备方法和应用 | |
CN115737748A (zh) | 一种治疗淋巴结核的外敷药 | |
CN107149665B (zh) | 一种治疗间质性肺疾病的中药及其制备方法 | |
KR20230058899A (ko) | 전통 한약 조성물 및 이의 제조 방법 | |
CN105412244A (zh) | 一种治疗妇科宫颈炎的中药组合物 | |
CN104042875B (zh) | 一种中药组合物及其制备方法和用途 | |
CN105267611A (zh) | 治疗皮肤病、乳腺增生或筋膜炎的中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210209 |